Corporate Derivative Sovereign Immunity Requires a James v. Jane Fact Inquiry (No Automatic Immunity for Hospital-Authority Subsidiaries)

I. Introduction

In Sentara Medical Group v. Klena (Supreme Court of Virginia, Feb. 26, 2026), Sentara Medical Group (“Sentara”) sued a departing physician, Dr. James W. Klena, for alleged breach of an employment agreement containing restrictive covenants, and also sued Chesapeake Regional Medical Group (“CRMG”) for tortious interference with that contract after CRMG hired him.

CRMG responded with a plea of sovereign immunity, arguing it shared immunity because it was a subsidiary created by the Chesapeake Hospital Authority (the “Authority”), a legislatively created public body empowered to operate medical facilities and to create or control affiliated entities. The circuit court sustained the plea and dismissed Sentara’s tortious-interference claim against CRMG with prejudice, relying on the premise that a subsidiary of an immune Authority automatically inherits the Authority’s immunity.

The Supreme Court of Virginia reversed, holding the circuit court lacked a sufficient factual basis to grant immunity on the pleadings and rejecting the notion of automatic derivative immunity for a corporate subsidiary.

II. Summary of the Opinion

  • The Court held that CRMG does not automatically share the Authority’s sovereign immunity merely because it is a subsidiary created by the Authority.
  • The Court explained that derivative immunity for an agent of an immune entity is not automatic; it typically requires a fact-specific inquiry (analogous to the analysis applied to employees).
  • The Court endorsed using the James v. Jane framework as an appropriate starting point for deciding whether a corporate agent shares a principal’s immunity, emphasizing a totality-of-the-circumstances approach.
  • Because CRMG offered no evidence (electing to rely solely on the complaint’s allegations), the record contained insufficient facts about CRMG’s structure, governance, and the Authority’s control—making it impossible to determine immunity.
  • Since CRMG bore the burden of proving immunity, the circuit court erred in sustaining the plea; the case was reversed and remanded.

III. Analysis

A. Precedents Cited

1. Procedure and standard of review on a plea decided on the pleadings

  • Massenburg v. City of Petersburg and Montalla, LLC v. Commonwealth: Because no evidence was taken, the Court treated the complaint’s allegations as true and afforded the plaintiff all reasonable inferences. This procedural posture constrained the immunity analysis to what was actually pleaded.
  • Fines v. Rappahannock Area Cmty. Servs. Bd.: Confirmed that when a circuit court hears no evidence on a plea, appellate review is confined to the pleadings.
  • Plofchan v. Plofchan: Supported the Court’s de novo review of whether the plea was correctly sustained.

2. Sovereign immunity’s purpose and baseline principles

  • City of Chesapeake v. Cunningham (quoting City of Virginia Beach v. Carmichael Dev. Co.): Provided the policy rationale—protecting governmental functions and preserving control of public funds and instrumentalities.
  • Gray v. Virginia Secy. of Transp. (quoting Board of Public Works v. Gannt): Reaffirmed the core sovereignty rule: the Commonwealth cannot be sued without consent.
  • Rector & Visitors of the Univ. of Va. v. Carter: Restated that absent an express waiver, the Commonwealth and its agencies are immune from tort liability for tortious acts/omissions of agents/employees.

3. The “sliding scale” of immunity across governmental actors

  • Seabolt v. County of Albemarle, citing Mann v. County Bd. of Arlington County and Fry v. County of Albemarle: Counties enjoy the Commonwealth’s tort immunity as political subdivisions.
  • Massenburg v. City of Petersburg: Municipal corporations have immunity for governmental, not proprietary, functions.
  • Carter v. Chesterfield Cnty. Health Comm'n, citing Virginia Elec. and Power Co. v. Hampton Redevelopment and Housing Authority and Hampton Roads Sanitation Dist. Com. v. Smith: Reinforced that “municipal corporation” immunity principles extend to other quasi-governmental municipal entities, depending on function.

4. Derivative/qualified immunity for agents and employees: the James/Messina framework

  • James v. Jane: Distinguished the Commonwealth’s “absolute” immunity from an employee’s at-most “qualified” immunity, and directed courts to examine function, state interest/involvement, discretion, and—critically—the degree of governmental control and direction.
  • Messina v. Burden: Applied James beyond state employees and articulated the now-familiar four factors: (1) nature of function, (2) government interest/involvement, (3) degree of control/direction, and (4) judgment/discretion.

5. Corporate agents and a persuasive trial-level analogue

  • Stevens v. Hospital Auth. of the City of Petersburg: Though not binding Supreme Court precedent, it directly addressed corporate defendants associated with an immune hospital authority and required those defendants claiming sovereign immunity to satisfy the James test after an evidentiary hearing. The Court treated Stevens as a helpful model and endorsed its use of the James framework as a starting point for corporate-agent immunity.

6. Burden of proof

  • Whitley v. Commonwealth: Established that the party claiming immunity bears the burden of proving entitlement—decisive here because CRMG produced no evidence.

B. Legal Reasoning

1. The Court rejected “automatic immunity by corporate lineage”

The circuit court effectively adopted a bright-line rule: if the Authority is immune and created CRMG as a subsidiary, then CRMG shares that immunity “as a matter of law.” The Supreme Court rejected that approach as inconsistent with the Court’s sovereign-immunity jurisprudence, which repeatedly refuses automatic extension of immunity to agents and employees.

A central logical move in the opinion is the analogy to employees: the Commonwealth must employ people to function, yet employees do not automatically inherit the Commonwealth’s immunity (James v. Jane). Likewise, an immune municipal authority may create supporting entities, but those entities do not automatically become immune simply by being created.

2. The Court also rejected the opposite extreme: “a subsidiary can never share immunity”

Sentara argued in substance that CRMG could only be immune if it independently qualifies as the Commonwealth, an agency, or a municipal corporation—effectively excluding derivative immunity for corporate agents. The Court rejected this as irreconcilable with James v. Jane and Messina v. Burden, which permit agents to share the principal’s immunity in appropriate circumstances.

3. A new, explicit methodological holding: corporate-agent immunity requires a fact-intensive inquiry using James as a starting point

The opinion’s key doctrinal development is the Court’s first explicit guidance (on this record) for assessing whether a corporate agent shares in a principal’s sovereign immunity. The Court held:

  • The James v. Jane framework is an appropriate starting point even though it was formulated for individuals.
  • The inquiry is totality-of-the-circumstances; “rarely will a single factor or circumstance prove dispositive.”
  • Relevant considerations include:
    • the corporate agent’s nature and structure;
    • the relationship between the agent and the immune principal;
    • the degree of control exerted by the principal or another governmental actor;
    • if the principal is a municipal corporation, whether the corporate agent was necessary or merely convenient to performing the governmental function;
    • the type of claim asserted—because actions beyond the scope of agency or exceeding authority/discretion do not share immunity (James v. Jane).

This is not a mechanical test and not a categorical rule; it is an evidentiary inquiry into whether the corporate defendant truly functioned as an extension of the immune entity’s governmental activity under governmental control.

4. The enabling act’s breadth heightened the need for limits

The Court underscored that the Authority’s enabling legislation authorizes it to acquire interests in a vast array of entities “organized for any purpose.” If mere authorization to create/acquire entities yielded automatic sovereign immunity, the immunity doctrine could expand dramatically— potentially immunizing entities far removed from governmental functions. The opinion therefore uses statutory breadth as a cautionary reason to insist on a fact-based derivative-immunity analysis rather than a per se rule.

5. Application: the record was insufficient, and CRMG bore the burden

On the pleadings, the Court knew only that CRMG was a subsidiary; shared a President/CEO with the Authority’s hospital; and employed some physicians working at the Authority’s hospital. The Court emphasized what it did not know: CRMG’s governance, how it operates, how it was created, and the degree of control exercised by the Authority or any government entity.

Because CRMG chose to offer no evidence, the Court held “it is impossible” to determine immunity—and because CRMG had the burden (Whitley v. Commonwealth), the plea should not have been sustained.

C. Impact

1. Practical effects on litigation involving hospital authorities and affiliated entities

  • No more automatic immunity for subsidiaries or affiliated corporate entities of immune municipal authorities. Defendants must prove immunity with facts.
  • Trial courts should expect (and often require) an evidentiary record—potentially including governance documents, bylaws, board composition, appointment/removal power, operational control, financial control, and the entity’s functional role in delivering governmental health services.
  • Plaintiffs can defeat early immunity pleas by highlighting missing facts and insisting the defendant carry its evidentiary burden.

2. Doctrinal significance: extending James/Messina logic to corporate agents

The Court did not create a rigid new test, but it did establish an important precedent: corporate derivative immunity is analyzed through the same functional-control lens that governs employee derivative immunity, adapted to corporate realities.

3. Likely downstream questions

  • How much governmental control is enough for a corporate entity (e.g., board appointment power, budget approval, indemnification, operational policies, or contractual performance standards)?
  • How will courts evaluate “necessary vs. convenient” corporate structuring in modern healthcare delivery?
  • In intentional tort contexts (like tortious interference), whether and when alleged conduct is deemed “beyond the scope” such that immunity cannot attach, even if the entity generally qualifies for derivative immunity.

IV. Complex Concepts Simplified

Sovereign immunity
A doctrine limiting when the Commonwealth and certain governmental entities can be sued in tort, intended to prevent interference with governmental functions and protect public funds.
Governmental vs. proprietary functions
For municipal corporations, immunity generally covers “governmental” activities (public duties) but not “proprietary” activities (more akin to private business operations). The Authority’s immunity was assumed, but CRMG’s derivative status required further analysis.
Absolute vs. qualified immunity
The Commonwealth and its agencies generally enjoy “absolute” immunity (absent waiver). Employees/agents may have “qualified” immunity, which depends on function, control, and discretion under James v. Jane and Messina v. Burden.
Derivative immunity
The concept that an agent (including potentially a corporate agent) may share the principal’s immunity, but only when the agent’s relationship to the governmental function and governmental control justifies it.
Plea of sovereign immunity / plea in bar
A defensive pleading seeking dismissal on immunity grounds. When decided without evidence, courts accept the complaint’s allegations as true and cannot assume facts that are not pleaded.
The James/Messina factors
A four-factor framework focusing on (1) function, (2) government interest/involvement, (3) government control/direction, and (4) discretion. The Court held this is an appropriate starting point for corporate-agent immunity too, assessed under the totality of circumstances.

V. Conclusion

Sentara Medical Group v. Klena establishes that a subsidiary or other corporate affiliate of an immune municipal hospital authority does not automatically inherit sovereign immunity. Whether a corporate agent shares a principal’s immunity requires a fact-intensive, totality-of-the-circumstances inquiry, with the James v. Jane framework serving as an appropriate starting point. Because CRMG offered no evidence and bore the burden of proof, the circuit court erred by sustaining the immunity plea. The decision meaningfully tightens the evidentiary and analytical discipline required before Virginia courts extend sovereign immunity beyond the governmental entity itself—especially in modern, corporatized public-healthcare structures.